Advertisement

Bisphosphonates can Reduce Osteoclastic Bone Resorption by Two Different Mechanisms

  • C. W. G. M. Löwik
  • P. M. Boonekamp
  • G. van de Pluym
  • L. van de Wee-Pals
  • H. Bloys van Treslong-de Groot
  • O. L. M. Bijvoet
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 208)

Abstract

Bisphosphonates (P-C-P’s) inhibit osteoclastic bone resorption (1). Their inhibitory potency has been clinically exploited with considerable benefit. The P-C-P’s have simplified the management of Paget’s disease (2,3) and of hypercalcemia of malignancy (4,5), both originating from excessive bone resorption. Three P-C-P’s have been investigated to a large extent, EHDP ((l-hydroxyethylidene)-1,1-bisphosphonate), Cl2MDP ((dichloromethylidene)-bisphosphonate) and APD ((3-amino-l-hydroxypropylidene)-1,1-bisphosphonate), yet their mechanism of action has remained uncertain. We have always found it disturbing that their relative potencies in-vitro and in-vivo differ (6,7)-In in-vitro cultures of explanted calvaria or radii C12MDP and EHDP exhibited the greatest potency (6) while the amino-bisphosphonate, APD, was the more potent clinically (3,4,8).

Keywords

Bone Resorption Relative Potency Millipore Filter Osteoclast Precursor Osteoclastic Bone Resorption 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    H. Fleisch. In: Bone and Mineral Research Annual I, p. 319. Ed. W.A. Peck, Excerpta Medica, Amsterdam-Oxford-Princeton (1982).Google Scholar
  2. 2.
    W.B. Frijlink, O.L.M. Bijvoet, J. te Velde and G. Heynen. Lancet i: 799–803 (1979).Google Scholar
  3. 3.
    P.J. Meunier, M.C. Chapuy, C. Alexandre, C. Bressot, C. Edouard, E. Vignon, L. Mathieu and U. Trechsel. Lancet ií: 489–492 (1979).Google Scholar
  4. 4.
    M.C. Chapuy, P.J. Meunier, C.M. Alexandre and E.P. Vignon. Eur. J. Clin. Invest. 65: 1243–1247 (1980).CrossRefGoogle Scholar
  5. 5.
    H.P. Sleeboom, O.L.M. Bijvoet, A.T. van Oosterom, J.H. Gleed and J.C.H. O’Riordan. Lancet i: 239–243 (1983).Google Scholar
  6. 6.
    T.P. Spiro and G.R. Mundy, Calcif. Tiss. Int. 31: 66 (1980).Google Scholar
  7. 7.
    M. Shinoda, G. Adamek, R. Felix, H. Fleisch, R. Schenk and P. Hagan. Calcif. Tiss. Int. 35: 87 (1983).CrossRefGoogle Scholar
  8. 8.
    H.I.J. Harinck, O.L.M. Bijvoet, H.J. Blanksma and P.J. DahlinghausNienhuys (in preparation).Google Scholar
  9. 9.
    T.J. Chambers. J. Clin. Pathol. 38: 241 (1985).CrossRefGoogle Scholar
  10. 10.
    E.H. Burger, J.W.M. van der Meer, J.S. van de Gevel, J.C. Gribnau, C.W. Thesingh and R. van Furth. J. Exp. Med. 156: 1604 (1982).Google Scholar
  11. 11.
    P.H. Reitsma, S.L. Teitelbaum, O.L.M. Bijvoet and A.J. Kahn. J. Clin. Invest. 70: 927 (1982).CrossRefGoogle Scholar
  12. 12.
    L.G. Raisz. J. Clin. Invest. 44: 103 (1965).CrossRefGoogle Scholar
  13. 13.
    C.W. Thesingh and E.H. Burger. Devel. Biol. 95: 429 (1983).CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • C. W. G. M. Löwik
    • 1
  • P. M. Boonekamp
    • 1
  • G. van de Pluym
    • 1
  • L. van de Wee-Pals
    • 1
  • H. Bloys van Treslong-de Groot
    • 1
  • O. L. M. Bijvoet
    • 1
  1. 1.Clinical Investigation Unit of the department of Clinical EndocrinologyUniversity Hospital Leidenthe Netherlands

Personalised recommendations